Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

- PMLiVE

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

There are more than 10,000 deaths due to liver disease each year in the UK

- PMLiVE

Sanofi/Regeneron’s Kevzara approved by FDA for polyarticular juvenile idiopathic arthritis

The chronic disease is designated as one of the three major types of juvenile idiopathic arthritis

- PMLiVE

Sanofi shares positive late-stage results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for uncontrolled COPD

No new treatment approaches have been approved for the respiratory disease in more than a decade

- PMLiVE

Sanofi’s multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

Biogen Idec building

Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition

The company will gain access to HI-Bio’s lead asset for immune-mediated and rare diseases

- PMLiVE

Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development

The companies will combine data, software and tuned models to bring new medicines to patients more efficiently

- PMLiVE

Sanofi and Regeneron share positive late-stage results for Dupixent in COPD

About 300,000 people in the US have uncontrolled COPD and evidence of type 2 inflammation

- PMLiVE

Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

- PMLiVE

Sanofi gains rights to Fulcrum’s muscular dystrophy treatment in deal worth more than $1bn

Losmapimod is being investigated as a potential transformative therapy for the rare disease

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn

The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links